Orphan drug profits windfall tax
Executive Summary
Rep. Stark's (D-Calif.) HR 3551 would permit orphan drug makers to recoup only 100% of the R&D costs plus a 25% annual profit during market exclusivity. "The Pink Sheet" incorrectly said the bill would permit manufacturers to recoup twice their investment (Oct. 21, p. 2); Stark's earlier bill (HR 1713) would have permitted the higher amount....